Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting
March 23 2017 - 7:05AM
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a
biopharmaceutical company committed to improving patient lives by
manufacturing high quality products for biotechnology and
pharmaceutical companies, and advancing its proprietary R&D
pipeline, today announced that four preclinical abstracts and one
clinical abstract have been accepted for presentation at the Annual
Meeting of the American Association for Cancer Research (AACR), to
be held April 1 - 5, 2017 in Washington, D.C.
Peregrine scientists and collaborators will
present positive findings from multiple studies of the company's
phosphatidylserine (PS)-targeting antibodies in combination with
other anti-tumor agents, including results from two Memorial Sloan
Kettering Cancer Center studies that evaluate the use of a
bavituximab equivalent in combination with immune stimulating
therapies. The following abstracts will be presented:
Abstract Number:
574Session: PO.IM02.02 - Checkpoints
1Presentation Title: Phosphatidylserine targeting
antibody in combination with tumor radiation and immune checkpoint
blockade promotes anti-tumor activity in mouse B16
melanomaPresentation Day/Time: Sunday, April 2,
2017, 1:00 - 5:00 PM EasternLocation: Section
25Poster Board Number: 8Author
Institutions: Memorial Sloan Kettering Cancer Center, New
York, NY; Peregrine Pharmaceuticals, Inc., Tustin, CA
Abstract Number:
1651Session: PO.IM02.08 - Tumor Microenvironment
and CheckpointsPresentation Title: Targeting
phosphatidylserine in combination with adoptive T cell transfer
eliminates advanced tumors without off-target toxicities in a
melanoma preclinical modelPresentation Day/Time:
Monday, April 3, 2017, 8:00 - 12:00 PM
EasternLocation: Section 27Poster Board
Number: 29Author Institutions: Memorial
Sloan Kettering Cancer Center, New York, NY; Peregrine
Pharmaceuticals, Inc., Tustin, CA
Abstract Number:
CT159Session: PO.CT02 - Phase III Clinical Trials
and Phase II/III Clinical Trials in ProgressPresentation
Title: IFN-γ analysis in blood and tissue as a potential
prognostic and/or predictive biomarkerPresentation
Day/Time: Monday, Apr 3, 2017 1:00 - 5:00 PM
EasternLocation: Section 33Poster Board
Number: 25Author Institution: Peregrine
Pharmaceuticals, Tustin, CA
Abstract Number: 3652Session:
PO.IM02.05 - BITES Bispecifics and CheckpointsPresentation
Title: Combinational activity of LAG3 and PD-1 targeted
therapies is significantly enhanced by the addition of
phosphatidylserine targeting antibodies and establishes an
anti-tumor memory response in murine triple negative breast
cancerPresentation Day/Time: Tuesday, April 4,
2017, 8:00 - 12:00 PM EasternLocation: Section
26Poster Board Number: 25Author
Institution: Peregrine Pharmaceuticals, Tustin, CA
Abstract Number:
3657Session: PO.IM02.05 - BITES Bispecifics and
CheckpointsPresentation Title:
Phosphatidylserine-targeting antibodies enhance anti-tumor activity
of a tumor vaccine in a HPV-induced tumor modelPresentation
Day/Time: Tuesday, April 4, 2017, 8:00 - 12:00 PM
EasternLocation: Section 26Poster Board
Number: 30Author Institutions:
Immunovaccine, Inc., Halifax, NS, Canada; Peregrine
Pharmaceuticals, Inc., Tustin, CA
Bavituximab is an investigational monoclonal
antibody that targets PS. Signals from PS inhibit the ability of
immune cells to recognize and fight tumors. Bavituximab is believed
to override PS mediated immunosuppressive signaling by blocking the
engagement of PS with its receptors as well as by sending an
alternate immune activating signal. Previous studies demonstrated
PS-targeting antibodies shift the functions of immune cells in
tumors, resulting in multiple signs of immune activation and
anti-tumor responses.
Peregrine's clinical development strategy for
bavituximab currently focuses on small, early-stage,
proof-of-concept trials evaluating the drug in combination with
other cancer treatments. As part of this approach the
National Comprehensive Cancer Network (NCCN) has awarded grants to
support three different clinical trials of bavituximab treatment
combinations. These trials will evaluate novel bavituximab
combinations in glioblastoma, head and neck cancer, and
hepatocellular carcinoma including an immunotherapy
combination. Additionally, Peregrine continues to advance its
pre-clinical collaboration with Memorial Sloan Kettering Cancer
Center with the goal of evaluating combinations of bavituximab with
other checkpoint inhibitors and immune stimulatory agents.
The intent behind this strategy is to focus our research and
development spending to further validate bavituximab's combination
potential as we seek to advance the program though a pharmaceutical
or biotechnology partner.
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of patients by delivering
high quality pharmaceutical products through its contract
development and manufacturing organization (CDMO) services and
through advancing and licensing its investigational immunotherapy
and related products. Peregrine's in-house CDMO services,
including cGMP manufacturing and development capabilities, are
provided through its wholly-owned subsidiary Avid Bioservices, Inc.
(www.avidbio.com), which provides development and biomanufacturing
services for both Peregrine and third-party customers. The
company is also working to evaluate its lead immunotherapy
candidate, bavituximab, in combination with immune stimulating
therapies for the treatment of various cancers, and developing its
proprietary exosome technology for the detection and monitoring of
cancer. For more information, please visit
www.peregrineinc.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024